Abstract: A receiver for a vacuum conveyance system may include a vertically-oriented, cylindrical receiver body having an inlet port through which material may be conveyed when an airstream is created. A head assembly attached to an upper end of the receiver body includes a filter housing having a first end and a second end, the filter housing constructed to house a horizontally-oriented cylindrical pre-filter between the first end and the second end, wherein the head assembly includes a filter access cap removably attached to the first end and usable to remove and insert cylindrical pre-filters. A vacuum utility assembly may be attached to the second end of the filter housing.

Abstract: An improved wheelchair assembly structured and arrange to equip a standard manual wheelchair with larger front wheels giving the user added leverage and control when maneuvering their chair.

Abstract: Disclosed are novel crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

Abstract: The insulated glass unit (IGU) of the present disclosure includes two or more glass panels that are spaced apart in a parallel arrangement. The panes define an interior space that is filled with air or other suitable gas, a fluid or liquid, or a vacuum. The IGU is encapsulated to provide a water-tight seal to prevent or minimize water or particles from migrating into the interior space, or to prevent or minimize heat loss. A spacer with a desiccant can be in the interior space. To preserve the structural integrity of the glass panels during encapsulation, a second spacer is placed between the glass panes. The second spacer can be T-shaped so that a narrowed body portion fits between the glass panes. The second spacer can also have a groove therein for storing adhesive and/or desiccant.

Abstract: Disclosed are novel crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, and solvates thereof and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.

Abstract: According to embodiments of the present invention, a material transfer station provides a base frame equipped with a table member, a container tipper, an operator interface, and a connection to a power source. In operation, a destination container is positioned beneath the table member, and the container tipper holds a supply container. Solid matter may be conveyed from the supply container into the destination container through an opening in the table member. Modules may be attached to provide additional functionality, such as a receiving module, a containment module, a vibratory screener, a flexible film isolator, and a nitrogen purge system.

Abstract: A hopper apparatus (100) provides a conveyance passage (150) equipped with a nitrogen purge system. In operation, the hopper apparatus (100) is installed over an opening of a process vessel (200). Chemical matter may be conveyed through the conveyance passage (150) to land within the process vessel (200). The hopper apparatus may have a flap valve (141) that serves to isolate the interior space of a process vessel (200) from the ambient environment outside the process vessel (200). The hopper apparatus (100) may also inject nitrogen at various rates into the falling stream of chemical matter as it is conveyed into a process vessel (200). The hopper apparatus (100) may also provide a ventilation sleeve (180) providing ventilation and extraction of dust and vapors emitted from the falling stream of chemical matter.

Abstract: The insulated glass unit (IGU) of the present disclosure includes two or more glass panels that are spaced apart in a parallel arrangement. The panes define an interior space that is filled with air or other suitable gas, a fluid or liquid, or a vacuum. The IGU is encapsulated to provide a water-tight seal to prevent or minimize water or particles from migrating into the interior space, or to prevent or minimize heat loss. A spacer with a desiccant can be in the interior space. To preserve the structural integrity of the glass panels during encapsulation, a second spacer is placed between the glass panes. The second spacer can be T-shaped so that a narrowed body portion fits between the glass panes. The second spacer can also have a groove therein for storing adhesive and/or desiccant.

Abstract: A hopper apparatus (100) provides a conveyance passage (150) equipped with a nitrogen purge system. In operation, the hopper apparatus (100) is installed over an opening of a process vessel (200). Chemical matter may be conveyed through the conveyance passage (150) to land within the process vessel (200). The hopper apparatus may have a flap valve (141) that serves to isolate the interior space of a process vessel (200) from the ambient environment outside the process vessel (200). The hopper apparatus (100) may also inject nitrogen at various rates into the falling stream of chemical matter as it is conveyed into a process vessel (200). The hopper apparatus (100) may also provide a ventilation sleeve (180) providing ventilation and extraction of dust and vapors emitted from the falling stream of chemical matter.

Abstract: An implantable medical device for releasing therapeutic agent having a medical device body and a plurality of reservoir-defining structures disposed on a surface of the body. A reservoir can be defined by the reservoir-defining structures and therapeutic agent may be located in the reservoir. A cover may extend over the reservoir so that the therapeutic agent is released from the reservoir when the medical device implanted. Methods for making the medical device may also include providing a medical device body, positioning a plurality of reservoir-defining structures on a surface of the body to form a reservoir, loading therapeutic agent into the reservoir, and covering the reservoir so that the therapeutic agent may release when the medical device is implanted. Alternatively, the reservoir may be covered with a cover and an opening formed in the cover so that the therapeutic agent may release when the medical device is implanted.

Abstract: The present invention relates to drug delivery compositions, drug delivery units, drug delivery devices and methods of making the same using nanofabrication processes. The nanofabrication processes are used to make pores in a matrix. Exemplary nanofabrication processes include nanoimprinting, reverse imprinting, nanolithography, and photolithography.

Abstract: An implantable medical device for releasing therapeutic agent having a medical device body and a plurality of reservoir-defining structures disposed on a surface of the body. A reservoir can be defined by the reservoir-defining structures and therapeutic agent may be located in the reservoir. A cover may extend over the reservoir so that the therapeutic agent is released from the reservoir when the medical device implanted. Methods for making the medical device may also include providing a medical device body, positioning a plurality of reservoir-defining structures on a surface of the body to form a reservoir, loading therapeutic agent into the reservoir, and covering the reservoir so that the therapeutic agent may release when the medical device is implanted. Alternatively, the reservoir may be covered with a cover and an opening formed in the cover so that the therapeutic agent may release when the medical device is implanted.

Abstract: This invention comprises an apparatus for treating an atherosclerotic plaque in a coronary artery of a mammal by placing at or proximate to an entrance to the coronary artery and upstream of the vulnerable plaque, and an effective amount of a therapeutic agent for the treatment of the plaque. This invention comprises delivering a deposition of a therapeutic drug high in the coronary arterial tree for treatment of downstream vulnerable plaques. The invention also comprises slow release formulation and delivery of an apparatus that is totally degradable or removed and/or replaced.

Abstract: The present invention relates to a device and method for delivery of a patch, graft, implant, therapeutic agent, or other device onto tissue using a rolled delivery mechanism. In one embodiment, a rolled delivery mechanism is provided for delivering a patch to tissue when the rolled delivery mechanism is unrolled. In another embodiment, a rolled delivery mechanism is provided for delivering therapeutic agent to a target tissue.

Abstract: A medical device comprising halofuginone is provided. The medical device is adapted for implantation or insertion into a blood vessel and it provides a cumulative, in vivo, 14 day release that lies between 0.02 ?g and 0.2 ?g of halofuginone per mm2 of stent surface area.

Abstract: A composite wall structure for use in a building, such as a geodesic dome, or the outer hull of a pressurized vehicle, such as an airship or submarine, is formed by interconnecting a plurality of three dimensional triangular shaped cells into a shape of desired contour, such as planar or curved, with each individual cell having a sealed chamber that is pressurized, and securing a fluid impervious closure skin to the connected array of cells. Each cell is formed by connecting planar rectangular sidewalls into a triangular frame having opposite sides and attaching a planar triangular panel to each side of the frame in a manner to form a pressure sealed chamber. The hull structure of predetermined shape is capable of captivating a volume of air and/or resisting buckling or failure resulting from fluid pressure on the hull during operation in air or water environments.

Abstract: A medical device is provided which is adapted for implantation or insertion into the vasculature. The medical device comprises the following: (a) a medical device substrate; (b) a lower polymeric layer, provided over the substrate, which comprises a nitric oxide donor and a polymer; and (c) an upper polymeric layer, provided over the lower polymer layer, which comprises a polymer and an anti-restenotic agent.

Abstract: An implantable or insertable medical device is provided which comprises (a) a superoxide dismutase mimic and (b) a polymeric release region. Upon administration to a patient, the polymeric release region controls the release of the superoxide dismutase mimic, which is beneficially selected from a metal-chelate superoxide dismutase mimic and a nitroxide superoxide dismutase mimic. Also provided is a method of making an implantable or insertable medical device.

Abstract: A method for producing a S-nitrosylated species is provided. The method comprises: (a) providing a deoxygenated, alkaline aqueous solution comprising a thiol and a nitrite-bearing species; (b) acidifying the solution by adding acid to the solution while concurrently mixing the solution (e.g., by vigorously stirring the solution) to produce the S-nitrosylated species; and (c) isolating the S-nitrosylated species. The nitrite-bearing species can be, for example, an inorganic nitrite, such as an alkali metal nitrite, or an organic nitrite, such as an alkyl nitrite (e.g., ethyl nitrite, amyl nitrite, isobutyl nitrite or t-butyl nitrite). The thiol is preferably a thiol-containing polysaccharide, a thiol-containing lipoprotein, a thiol-containing amino acid or a thiol-containing protein, and more preferably a thiol-containing polysaccharide such as thiolated cyclodextrin. In many preferred embodiments, the S-nitrosylated species is insoluble in the acidified solution, precipitating upon formation.

Abstract: The present invention relates generally to medical devices, preferably a stent, comprising an amount of one or more therapeutic agents, preferably paclitaxel, useful for preventing or treating a disease or condition associated with cell proliferation and/or migration. In particular, the invention relates to medical devices that is capable of releasing a cytostatic amount of paclitaxel that is effective to arrest smooth muscle cells in their G1/S phase without killing the cells. The medical devices can also release paclitaxel at a predetermined rate. Methods of making and using the medical devices are also provided.